VivoSeq
Other

Female

0

Pipeline Programs↗

12

Active Trials↗

59

Companies Involved↗

Female is an early-stage landscape with 0 programs across 59 companies. The most active players are Boehringer Ingelheim, AstraZeneca, GSK.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

32/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalAstellas logo

Astellas

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

291

clinical trials

Completed252 · 87%
Terminated11 · 4%
Unknown status8 · 3%
Withdrawn6 · 2%
Recruiting5 · 2%
Not yet recruiting4 · 1%
Other5 · 2%

Clinical Trials

Trial Activity

291 trials

A Study of Elenestinib in Healthy Adult Female Participants
Recruiting·BBlueprint Medicines·Phase 1·NCT07388511·20 enrolled
A Study of RSLV-132 in Females With Sjögren's Disease
Recruiting·RResolve Therapeutics·Phase 2·NCT06440525·106 enrolled
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
Recruiting·XXiamen Amoytop Biotech Co., Ltd.·Phase 1·NCT06924385·30 enrolled
Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients
Recruiting·—·N/A·NCT05966727·20 enrolled
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers
Recruiting·KKashiv BioSciences, LLC·Phase 1·NCT06995482·40 enrolled
A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 1·NCT06580587·12 enrolled
Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers
Active, not recruiting·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 1·NCT06864793·48 enrolled
Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
Active, not recruiting·MMidway Specialty Care Center·N/A·NCT06145854·100 enrolled
A Study to Assess the Mass Balance of [14C]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects.
Not yet recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 1·NCT07320521·6 enrolled
Saphnelo Use in Females of Child-bearing Potential
Not yet recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07431775·26,000,000 enrolled
A Clinical Study of V540A in Healthy Female Participants (V540A-005)
Not yet recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT07224477·525 enrolled
Evaluation of a Mobile Menopause Application
Not yet recruiting·EEndo Health GmbH·Preclinical·NCT07663305·426 enrolled
A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects
Completed·NNeurocrine UK Limited·Phase 1·NCT03311932·51 enrolled
Test the Outdoor Usage for Sunscreen Products in Female Adults
Completed·Bayer logoBayer·N/A·NCT02779270·105 enrolled
Do Oral Contraceptives Protect Against ACL Injuries in Female Athletes
Completed·—·Phase 4·NCT04899778·73 enrolled
Page 1 of 20

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)